This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Medbox CEO Gives Testimony To DPH Regarding Program Implementation In Massachusetts

HOLLYWOOD, Calif., Feb. 15, 2013 /PRNewswire/ -- Medbox, Inc. (OTC Markets: MDBX) ( www.medboxinc.com), announced that their CEO, Dr. Bruce Bedrick, gave testimony earlier in the week to the Department of Public Health in support of sensible regulations and overall implementation of the medical marijuana program in Massachusetts. 

Dr. Bedrick was one of the first few speakers Wednesday in Worcester and gave testimony, in a standing room only crowd, directly to the DPH whom is charged with implementing the rules and procedures governing the Massachusetts medical marijuana program. Dr. Bedrick proposed easy and convenient access for patients to receive their medicine, but also suggested strict regulatory oversight to prevent abuse and diversion. Massachusetts will only be authorizing a total of 35 dispensaries licenses for the entire state and it is believed that the licensing of the facilities will be finalized by the end of this year.

The CEO was then off to Colorado Thursday where he presented the Amendment 64 advisory panel with an overview of the Medbox technology and how it would be used in Colorado to track taxation, limit abuse, and control inventory more effectively. The appearance in Colorado coincides with a news story on Fox News Denver (KDVR) that is set to air Wednesday February 20 th at 9pm central that prominently features the Medbox technology and has interviews with Dr. Bedrick and an operator that utilizes the Medbox equipment in her dispensary to manage day-to-day operations.

"We are thrilled that regulatory agencies around the country are allowing us to speak with them on how to create a safe, compliant, and transparent model for operation," stated Dr. Bedrick. "Medbox prides itself on being an industry leader and an integral part of the solution and never part of the problem."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,096.90 -106.47 -0.58%
S&P 500 2,098.53 -9.25 -0.44%
NASDAQ 4,967.1410 -12.76 -0.26%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs